(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603590 · · 14 pages · Chinese
Beijing Konruns Pharmaceutical Co., Ltd. on 6ix
Earlier from Beijing Konruns Pharmaceutical
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Receipt of Clinical Trial Approval Notice for KC1086 Combined with Fulvestrant for the Treatment of HR+HER2- Locally Advanced or Metastatic Breast Cancer
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Implementation Results of Share Repurchase and Share Changes
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Resolutions of the 7th Meeting of the 5th Board of Directors
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Repurchase and Cancellation of Restricted Shares Granted to Certain Incentive Participants but Not Yet Released from Trading Restrictions
Later from Beijing Konruns Pharmaceutical
All Beijing Konruns Pharmaceutical news releasesFollow Beijing Konruns Pharmaceutical into a list and get an email when it puts out news.
Follow Beijing Konruns Pharmaceutical